Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. 2007

Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine protein kinase and its deregulation is implicated in a number of neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Using active site homology modeling between CDK5 and CDK2, we explored several different chemical series of potent CDK5 inhibitors. In this report, we describe the design, synthesis, and CDK5 inhibitory activities of quinolin-2(1H)-one derivatives.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011804 Quinolines
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D051357 Cyclin-Dependent Kinase 2 A key regulator of CELL CYCLE progression. It partners with CYCLIN E to regulate entry into S PHASE and also interacts with CYCLIN A to phosphorylate RETINOBLASTOMA PROTEIN. Its activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P27 and CYCLIN-DEPENDENT KINASE INHIBITOR P21. Cdk2 Protein Kinase,CDK2 Protein,Cdc2-Related Protein Kinase,p33cdk2 Kinase,Cdc2 Related Protein Kinase,Cyclin Dependent Kinase 2
D051360 Cyclin-Dependent Kinase 5 A serine-threonine kinase that plays important roles in CELL DIFFERENTIATION; CELL MIGRATION; and CELL DEATH of NERVE CELLS. It is closely related to other CYCLIN-DEPENDENT KINASES but does not seem to participate in CELL CYCLE regulation. Cdk5 Protein Kinase,Cdc2-Related Kinase PSSALRE,Cdk5 Protein,Neuronal Cdc2-Like Protein Kinase,PSSALRE Protein,Cdc2 Related Kinase PSSALRE,Cyclin Dependent Kinase 5,Neuronal Cdc2 Like Protein Kinase,PSSALRE, Cdc2-Related Kinase,Protein Kinase, Cdk5

Related Publications

Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
September 2004, Bioorganic & medicinal chemistry letters,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
February 2023, Bioorganic & medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
September 2018, European journal of medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
January 2024, Bioorganic & medicinal chemistry letters,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
January 2015, Bioorganic & medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
April 2023, Archiv der Pharmazie,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
December 2020, European journal of medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
October 2019, European journal of medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
January 2015, Anti-cancer agents in medicinal chemistry,
Wenge Zhong, and Hu Liu, and Matthew R Kaller, and Charles Henley, and Ella Magal, and Thomas Nguyen, and Timothy D Osslund, and David Powers, and Robert M Rzasa, and Hui-Ling Wang, and Weiya Wang, and Xiaoling Xiong, and Jiandong Zhang, and Mark H Norman
April 2013, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!